AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022

31 May 2022 16:01:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held in New York from June 8 – 10, 2022

27 May 2022 07:45:51 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present Four Clinical Data Updates at the European Hematology Association Congress

12 May 2022 10:51:46 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress

05 May 2022 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022 

02 May 2022 16:31:00 By Nasdaq GlobeNewswire

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

25 Apr 2022 07:01:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

25 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia

31 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics to Participate in Conferences During April 2022

29 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

10 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 10

21 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces retirement of chief financial officer and succession plan

10 Jan 2022 07:01:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces 2022 priorities

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present at Conferences During January 2022

05 Jan 2022 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition

13 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Autolus Therapeutics announce new time for investor call to discuss data presented at the 63rd ASH Annual Meeting & Exposition

06 Dec 2021 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director

15 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells

10 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

08 Nov 2021 02:00:00 By Nasdaq GlobeNewswire